2023
Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism
Lomakin I, Devarkar S, Patel S, Grada A, Bunick C. Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism. Nucleic Acids Research 2023, 51: 2915-2930. PMID: 36864821, PMCID: PMC10085706, DOI: 10.1093/nar/gkad103.Peer-Reviewed Original Research
2022
Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity
Grada A, Del Rosso J, Moore A, Gold L, Harper J, Damiani G, Shaw K, Obagi S, Salem R, Tanaka S, Bunick C. Reduced blood-brain barrier penetration of acne vulgaris antibiotic sarecycline compared to minocycline corresponds with lower lipophilicity. Frontiers In Medicine 2022, 9: 1033980. PMID: 36569144, PMCID: PMC9773825, DOI: 10.3389/fmed.2022.1033980.Peer-Reviewed Original ResearchAdverse eventsClinical trialsVestibular side effectsBlood-brain barrier penetrationSecond-generation tetracyclineNon-clinical studiesLower ratesH postdosingAcne vulgarisSide effectsMinocyclineBrain samplesPotential associationSarecyclineBarrier penetrationDoxycyclineTrialsLow lipophilicityPenetranceTetracyclineDizzinessVertigoPostdosingRosaceaAcneAntibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris
Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris. Antibiotics 2022, 11: 1032. PMID: 36009899, PMCID: PMC9405006, DOI: 10.3390/antibiotics11081032.Peer-Reviewed Original ResearchAcne vulgarisSevere acne vulgarisAntibiotic resistancePotential side effectsOral tetracyclineGut dysbiosisPatients 9Gastrointestinal upsetRisk of resistanceSide effectsDrug AdministrationTetracycline treatmentSarecyclineTetracycline usageAcneTreatmentTetracyclineAntibiotic resistance riskPathogenic bacteriumRiskVulgarisDizzinessVertigoDysbiosisMinocyclineSarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota
Ghannoum MA, Long L, Bunick CG, Del Rosso JQ, Gamal A, Tyring SK, McCormick TS, Grada A. Sarecycline Demonstrated Reduced Activity Compared to Minocycline against Microbial Species Representing Human Gastrointestinal Microbiota. Antibiotics 2022, 11: 324. PMID: 35326788, PMCID: PMC8944611, DOI: 10.3390/antibiotics11030324.Peer-Reviewed Original ResearchMinimum inhibitory concentrationVitro minimum inhibitory concentrationHigh minimum inhibitory concentrationsTetracycline-class antibioticsTime-kill assaysBroad-spectrum tetracycline antibioticTime-kill kinetic assayGastrointestinal tract microbiotaHigh MIC valuesHuman gastrointestinal microbiotaLess activityAcne treatmentGut microbiotaMinocyclineGut microbiomeGastrointestinal microbiotaSarecyclineInhibitory concentrationGut microorganismsSkin microbiomeVivo testingReduced activityMicrobiotaMIC valuesAntibiotics
2021
Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation
Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics 2021, 10: 439. PMID: 33920812, PMCID: PMC8071131, DOI: 10.3390/antibiotics10040439.Peer-Reviewed Original ResearchTetracycline-class antibioticsBroad-spectrum antibiotic useRat paw edema modelPaw edema modelAnti-inflammatory activityWound infection modelSevere acneEdema modelPatient outcomesAntibiotic useMurine modelAnimal modelsDrug AdministrationGut microfloraInfection modelSarecyclineVivo studiesRelevant Gram-positive bacteriaReduced efficacyInfectionAntimicrobial resistanceVivo activityAntibiotic resistanceInflammationReduced activitySarecycline Demonstrates Narrow spectrum Antibacterial Activity and Anti inflammatory Effect in Animal Models
Bunick C, Del Rosso J, Tyring S, Draper M, Johnson J, Grada A. Sarecycline Demonstrates Narrow spectrum Antibacterial Activity and Anti inflammatory Effect in Animal Models. SKIN The Journal Of Cutaneous Medicine 2021, 5: s14. DOI: 10.25251/skin.5.supp.14.Peer-Reviewed Original Research